drugset
drugset / Trial / NCT01024101

Early Phase II Study of Weekly Paclitaxel (BMS-181339) in Patient With Advanced or Recurrent Head and Neck Cancer

NCT01024101 ↗

Phase 2 Completed 36 enrolled Bristol-Myers Squibb
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the efficacy and the safety of paclitaxel given weekly in patients with advanced or recurrent head and neck cancer

Timeline

Start
2004-01
Primary completion
2005-12
Completion
2005-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Paclitaxel Small molecule 100 mg/m2 Intravenous

Indications

head and neck cancer